Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2023)
Fast tracking informative clinical trials: lessons for mental health.
Gold SM. et al, (2023), Lancet psychiatry
Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
LANDRAY M. et al, (2023), The lancet
Facilitating participation in clinical trials during pregnancy.
Vousden N. et al, (2023), Bmj, 380
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney int
A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
Johansen ND. et al, (2023), Nejm evidence, 2
Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation.
Bowman L. et al, (2022), Eur heart j
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2022), N engl j med
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2022)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Staplin N. et al, (2022), Hypertension
Data provenance and integrity of health-care systems data for clinical trials.
Murray ML. et al, (2022), Lancet digit health, 4, e567 - e568
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
Peto L. et al, (2022), Adv biol regul
Allocated but not treated: the silent 16% - Authors' reply.
Horby P. et al, (2022), Lancet, 399, 1775 - 1776
Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting: Rationale and Design of the DANFLU-1 Trial
LANDRAY M., (2022), Pilot and feasibility studies
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur heart j, 43, 1416 - 1424